Stock Analysis
- South Korea
- /
- Personal Products
- /
- KOSDAQ:A900120
CXI Healthcare Technology Group First Quarter 2025 Earnings: EPS: ₩21.00 (vs ₩35.00 in 1Q 2024)
CXI Healthcare Technology Group (KOSDAQ:900120) First Quarter 2025 Results
Key Financial Results
- Revenue: ₩18.2b (down 9.9% from 1Q 2024).
- Net income: ₩6.25b (down 11% from 1Q 2024).
- Profit margin: 34% (in line with 1Q 2024).
- EPS: ₩21.00 (down from ₩35.00 in 1Q 2024).
All figures shown in the chart above are for the trailing 12 month (TTM) period
CXI Healthcare Technology Group shares are down 4.1% from a week ago.
Risk Analysis
You still need to take note of risks, for example - CXI Healthcare Technology Group has 3 warning signs (and 1 which is concerning) we think you should know about.
New: AI Stock Screener & Alerts
Our new AI Stock Screener scans the market every day to uncover opportunities.
• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies
Or build your own from over 50 metrics.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A900120
CXI Healthcare Technology Group
Engages in the manufacture and distribution of health foods.